HIV treatment bulletin

RSS Atom • ISSN 1472-4683 • Subscribe • About

2002

Next page

• Europe steps in to protect discounted drugs for developing countries Treatment access - 1 December 2002

• Protecting mothers from mono and dual therapies, and considering the value of Caesarean sections Meeting report - 1 December 2002

• Boosted PIs: differences emerging in efficacy, tolerability, lipids Antiretrovirals - 1 December 2002

• Europe steps in to protect discounted drugs for developing countries Antiretrovirals - 1 December 2002

• Hair analysis may help determine drug levels, adherence and virological response Antiretrovirals - 1 December 2002

• Disadvantage from prior nucleoside therapy persists for years during HAART Antiretrovirals - 1 December 2002

• Perspectives on hormonal, mitochondrial and metabolic changes Lipodystrophy and metabolic complications - Side effects - 1 December 2002

• IAS panel issues first guidelines for HIV and HIV drug-related metabolic complications Lipodystrophy and metabolic complications - Side effects - 1 December 2002

• Side effects are a common cause of intentional non adherence to HAART Side effects - 1 December 2002

• PML-associated immune restoration disease associated with mortality Opportunistic infections and complications - 1 December 2002

• Animal retroviral infections suggest third kind of potential treatment: HIV harm reduction Basic science and immunology - Virology - 1 December 2002

• Memory T cells do not recognise circulating HIV in late infection Basic science and immunology - 1 December 2002

• Chiron halts major IL-2 study, for business reasons Other news - 1 December 2002

• EU increases powers, and speeds up actions, of the European medicines agency Other news - 1 December 2002

• Zinc treatment for diarrhoea reduces child deaths Other news - 1 December 2002

• Post-meeting coverage of the 42nd ICAAC On the web - 1 December 2002

• AIDS-related malignancies in the era of HAART On the web - 1 December 2002

• Screening for and treatment of anal intraepithelial neoplasia On the web - 1 December 2002

• Coping with lipodystrophy’s emotional toll On the web - 1 December 2002

• Beyond HAART: a closer look at immune therapies On the web - 1 December 2002

• Digging deeper at the resistance workshop On the web - 1 December 2002

• Medscape conference coverage On the web - 1 December 2002

• Anaemia, neutropenia, and thrombocytopenia: pathogenesis and evolving treatment options in HIV-infected patients On the web - 1 December 2002

• Comprehensive health care for people infected with HIV in developing countries BMJ 2002;325:954-957 On the web - 1 December 2002

• Anti-R7V antibodies may protect some HIV-infected patients from developing AIDS: a conversation with Jean-Claude Chermann On the web - 1 December 2002

• Combining saquinavir with lopinavir/ritonavir? On the web - 1 December 2002

• Glossary of HIV/AIDS-Related Terms, 4th ed On the web - 1 December 2002

• HIV and Its Treatment: What You Should Know, 2nd edition On the web - 1 December 2002

• Volume 3 Number 10 December 2002 PDF PDFs - 1 December 2002

• Profiteers undermine preferential pricing and make millions diverting cheap drugs sent to Africa Treatment access - 13 November 2002

• Activists win court battle in campaign for generic production of ddI Treatment access - 13 November 2002

• Global AIDS fund facing bankruptcy Treatment access - 13 November 2002

• 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002 Conference reports - Conference index - ICAAC 42nd San Diego 2002 - 13 November 2002

• Immunology and treatment interruption data presented at the 42nd ICAAC Conference reports - Treatment strategies - ICAAC 42nd San Diego 2002 - 13 November 2002

• Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3 Conference reports - Treatment strategies - ICAAC 42nd San Diego 2002 - 13 November 2002

• Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL Conference reports - Treatment strategies - ICAAC 42nd San Diego 2002 - 13 November 2002

• Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients Conference reports - Other news - ICAAC 42nd San Diego 2002 - 13 November 2002

• BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients Antiretrovirals - Conference reports - ICAAC 42nd San Diego 2002 - 13 November 2002

• Adverse drug reactions and lipodystrophy in children Conference reports - Paediatric care - Side effects - ICAAC 42nd San Diego 2002 - 13 November 2002

• Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir Conference reports - ICAAC 42nd San Diego 2002 - 13 November 2002

• Novel approaches to the inhibition of HIV Conference reports - ICAAC 42nd San Diego 2002 - 13 November 2002

• Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC Conference reports - Lipodystrophy and metabolic complications - Side effects - ICAAC 42nd San Diego 2002 - 13 November 2002

• 4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002 Conference reports - Conference index - Lipodystrophy Workshop (IWADRLH) 4 San Diego 2002 - 13 November 2002

• Leptin, lipodystrophy and insulin resistance Conference reports - Lipodystrophy Workshop (IWADRLH) 4 San Diego 2002 - 13 November 2002

• A range of treatments for facial lipoatrophy Conference reports - Lipodystrophy and metabolic complications - Side effects - Lipodystrophy Workshop (IWADRLH) 4 San Diego 2002 - 13 November 2002

• Autopsy evidence confirms that ARVs tackle CNS lesions Basic science and immunology - Conference reports - 13 November 2002

• New evidence favours routine measurement of plasma concentrations in salvage therapy to maintain sustained drug levels Antiretrovirals - 13 November 2002

• New safety information for ddI used with ribavirin Antiretrovirals - Treatment alerts - 13 November 2002

• US FDA issues new safety information for tenofovir co-administration with ddI Antiretrovirals - Treatment alerts - 13 November 2002

• European Commission approves new boosted saquinavir regimen (1000 mg saquinavir/100 mg ritonavir twice daily) for the treatment of HIV-1 Antiretrovirals - 13 November 2002

• Tamoxifen for male breast enlargement? Lipodystrophy and metabolic complications - Side effects - 13 November 2002

• Diet can help reduce lipid levels in people with HAART-related dyslipemia Lipodystrophy and metabolic complications - Side effects - 13 November 2002

• HAART enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women Cancer and HIV - Women's health - 13 November 2002

• Study shows why some immune systems can control HIV through CD8 cells Basic science and immunology - 13 November 2002

• Intestinal worm eradication lowers viral load in HIV-positive patients Opportunistic infections and complications - 13 November 2002

• PPAR agonists inhibit HIV replication and TNF-alpha production Basic science and immunology - 13 November 2002

• Many HIV-infected CD4 cells are HIV-specific in patients on HAART Basic science and immunology - 13 November 2002

• Milk thistle can reduce levels of indinavir in the blood PK and drug interactions - 13 November 2002

• The Children's HIV Association of the UK and Ireland – CHIVA Other news - 13 November 2002

• Highlights of the autumn CHIVA meeting Other news - 13 November 2002

• Multivitamins limit HIV transmission through breastfeeding for some women Other news - 13 November 2002

• Prison health services will be taken over by the NHS from next year Other news - 13 November 2002

• Diagnosis and management of hepatitis C On the web - 13 November 2002

• HIV-1-associated dementia: a basic science and clinical perspective On the web - 13 November 2002

• Clinicians debate antiretroviral tactics and toxicities, resistance testing, and hepatitis virus coinfection On the web - 13 November 2002

• Lipodystrophy syndrome and self-assessment of wellbeing and physical appearance in HIV-positive patients Lipodystrophy and metabolic complications - Side effects - 1 November 2002

• Multivitamins limit HIV transmission through breastfeeding for some women Other news - 1 November 2002

• Prison health services will be taken over by the NHS from next year Other news - 1 November 2002

• Lymphoma in the setting of HIV disease On the web - 1 November 2002

• Mitochondrial toxicity in HAART On the web - 1 November 2002

• Mechanisms of T-cell depletion and repletion in HIV disease On the web - 1 November 2002

• HAART interruption strategies: how, when & why? On the web - 1 November 2002

• HIV/AIDS related Spanish language sites, from thirteen different countries. On the web - 1 November 2002

• New treatment information from Visionary Health Concepts On the web - 1 November 2002

• The Guide to Lipodystrophy in HIV On the web - 1 November 2002

• LIPOWatch On the web - 1 November 2002

• Fat in the blood On the web - 1 November 2002

• Current status of ARV treatment interruption and intermittent therapy strategies On the web - 1 November 2002

• Pathogenesis and epidemiology of metabolic abnormalities On the web - 1 November 2002

• Management of morphologic changes during antiretroviral therapy: insights from etiology On the web - 1 November 2002

• Entry inhibitors On the web - 1 November 2002

• Mitochondrial toxicity On the web - 1 November 2002

• HIV medicine after the Barcelona conference: interview with Howard Grossman MD On the web - 1 November 2002

• Once-daily antiretroviral options On the web - 1 November 2002

• Volume 3 Number 9 November 2002 PDF PDFs - 1 November 2002

• Excitement over anticipated approval of T-20 is balanced by fears that it will be the most expensive HIV drug yet Treatment access - 13 October 2002

• GlaxoSmithKline cuts drug prices to 63 countries Treatment access - 13 October 2002

• Integrase inhibitors enter trials in human volunteers Other news - 13 October 2002

• US HIV community hold productive meeting with Schering-Plough on new anti-HIV entry inhibitors SCH-C and SCH-D Antiretrovirals - 13 October 2002

• Notes on Schering-Plough/HIV community meeting held August 28 2002 Antiretrovirals - 13 October 2002

• US FDA announces important changes in amprenavir product labelling Antiretrovirals - PK and drug interactions - 13 October 2002

• Antiretrovirals could stop HIV epidemic – optimism or realism? Other news - 13 October 2002

• Much lower dose of lamivudine needed for HIV-positive patients on dialysis Antiretrovirals - 13 October 2002

• M184V is associated with decreased development of TAMs Resistance - 13 October 2002

• Patients discontinuing HAART must be carefully monitored Antiretrovirals - 13 October 2002

• Antiretrovirals have neurologic benefits in children Paediatric care - 13 October 2002

• Early data highlight ribavirin's anti-adenovirus potential Paediatric care - 13 October 2002

• Updated recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States Guidelines - 13 October 2002

• St John’s Wort interferes with chemotherapy, study shows Cancer and HIV - PK and drug interactions - 13 October 2002

• Dutch researchers theorise chimpanzees may have survived AIDS epidemic two million years ago Other news - 13 October 2002

Next page